VirginiaCancerRx:
A Symposium on Drug Discovery for Cancer
May 30-31, 2017
Darden Center
Charlottesville, VA

Day 1 (Tuesday, May 30, 2017) Chairs: Nicholas P. Farrell and David Kingston

10:00 am  Registration opens

11:00 am  Entrepreneurial workshop (11:00 am to 1:00 pm) with lunch. David Touve, Assistant Professor, Director, The Galant Center for Entrepreneurship, UVA; Robert J. Creeden, Managing Director, UVA Seed Fund & New Ventures; Magdalena K. Morgan, Technology Manager, VCU Innovation Gateway

1:00 pm  Symposium Opens: Welcome from organizers and meeting purpose, John Lazo

1:10 pm  Welcome talks
Thomas P. Loughran, Director, UVA Cancer Center, “Cancer Research at UVA”
Skip Trump, CEO and Executive Director Inova Schar Cancer Institute, “Cancer Research at INOVA”
Michael J. Friedlander, Founding Executive Director, Virginia Tech Carilion Research Institute, Vice President for Health Sciences and Technology, Virginia Tech, Senior Dean for Research, Virginia Tech Carilion School of Medicine, “Cancer Research at Virginia Tech”
O. John Semmes, Director, EVMS Leroy T. Canoles, Jr. Cancer Research Center, “Cancer Research at Eastern Virginia Medical School”
Gordon Ginder, Director, Massey Cancer Center at VCU, “Cancer Research at VCU”

2:30 pm  Keynote 1: Barbara Slusher, Professor of Neurology, Medicine, Psychiatry, and Neuroscience; Director of the Johns Hopkins Drug Discovery Program; Director, Academic Drug Discovery Consortium. “Discovering Drugs in Academia”.

3:15 pm  Q & A

3:20 pm  Coffee break/Poster Session 1

5:00 pm  Short contributed talks
i. Steve Grossman, Deputy Director, Massey Cancer Center and Chair, Division of Hematology Oncology and Palliative Care, Department of Internal Medicine, VCU School of Medicine “It can be done…..small molecule inhibition of the oncogenic transcription factor CtBP”??
ii. John Bushweller, Professor of Molecular Physiology & Biological Physics and Chemistry, UVA “Targeting Undruggable Cancer Targets.”
iii. David Kingston, University Distinguished Professor, Department of Chemistry, Virginia Tech “Nanoparticle delivery of anticancer drugs”
iv. Mariaelena Pierobon, GMU

6:30 pm  Social Hour & Networking
7:00 pm  Dinner
8:00 pm  Keynote 2: Craig M. Crews, Lewis B. Cullman Professor of Molecular, Cellular, and Developmental Biology, Chemistry and Pharmacology; Executive Director, Yale Center for Molecular Discovery. PROTACS: Induced Protein Degradation as a Therapeutic Strategy
8:45 pm  Q & A

Day 2 (Wednesday, May 31, 2016). Chairs: Elizabeth Sharlow and Paul Carlier

7:00 am  Breakfast
8:30 am  Welcome to Day 2. John Lazo
8:35 am  Keynote 3 Rob Kramer. CSO, RAKramer Consulting LLC; CSO SalvaRx Group PLC; CSO, Sonnet Biotherapeutics. former Vice President of Bristol Myers and VP and Head of Discovery for Oncology Therapeutics at Janssen Research & Development. Cancer Drug Discovery and Development in the Immune Oncology era, this is not your father’s Oldsmobile
9:20 am  Q & A
9:25 am  Short contributed talks
   i. Tim Errington, Metascience Manager, Center for Open Science, “Increasing Reproducibility and Openness in Cancer Research.”
   ii. Richard Heller Professor & Eminent Scholar, Frank Reidy Center for Bioelectrics, Old Dominion University. “Nonviral Delivery of Plasmids Encoding Cytokines as an Effective Therapeutic Approach for Melanoma.”
   iii. O. John Semmes, Professor, Department, Department of Microbiology and Molecular Cell Biology, EVMS, “Development of liquid-biopsies for personalized care in prostate cancer”
   iv. Samy Lamouille, Research Assistant Professor, Virginia Tech Carilion Research Institute “Targetting Glioblastoma Cancer Stem Cells with a Novel Connexin43 Mimetic Peptide”
   v. Kevin Janes, Associate Professor, Department of Biomedical Engineering, UVA, “Predictive Modeling of Signal-Transduction Networks”
10:55 am   Coffee break/poster session
12:25 pm   Lunch and Networking
1:30 pm   Short graduate student/postdoc poster talks
2:00 pm   Keynote 4 Otis Brawley, Chief Medical and Scientific Officer and Executive Vice President of the American Cancer Society. How Do Societies and Foundations Supporting Cancer Drug Discovery?
2:45 pm   Q & A
2:50 pm   Future plans: partnership and funding opportunities
3:20 pm   Closing Remarks. David Kingston, John Lazo and Richard Glennon
3:30 pm   Conference ends